SCHEMBL4069571

SCHEMBL4069571

NC(=S)c1ncccc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 1/20 0.46
RRM2 P31350 1/20 0.46
RRM2B Q7LG56 1/20 0.46
CISD1 Q9NZ45 1/20 0.46
GRM4 Q14833 1/20 0.41
MAPT P10636 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
HSP90AA1 P07900 4/20 0.38
HSP90AB1 P08238 3/20 0.38
IDO1 P14902 1/20 0.38
PSMB5 P28074 1/20 0.38
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
BLM P54132 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454171 0.80 GRM4 (0.41) RRM1RRM2RRM2BCISD1GRM4
SCHEMBL29385675 0.80 MKNK1 (0.49) GRM4MAPTL3MBTL1CYP3A4CYP1A2
SCHEMBL699068 0.80 MKNK1 (0.49) GRM4MAPTL3MBTL1CYP3A4CYP1A2
Hydrochloric Acid SCHEMBL7958246 0.78 GRM4 (0.40) RRM1RRM2RRM2BCISD1GRM4
SCHEMBL20558075 0.77 GRM4 (0.49) GRM4MAPTL3MBTL1HSP90AA1HSP90AB1
SCHEMBL27543664 0.77 MAPT (0.47) MAPTL3MBTL1CYP3A4CYP1A2BLM
SCHEMBL8847897 0.77 EGLN2 (0.44) MAPTL3MBTL1HSP90AA1HSP90AB1IDO1
SCHEMBL7960810 0.77 RRM1 (0.39) RRM1RRM2RRM2BCISD1GRM4
SCHEMBL6461091 0.77 RRM1 (0.39) RRM1RRM2RRM2BCISD1GRM4
SCHEMBL7960813 0.77 RRM1 (0.39) RRM1RRM2RRM2BCISD1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822127-B2 GAK modulators as antivirals THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-11-21 US disclosed
US-20170152271-A1 GAK MODULATORS AS ANTIVIRALS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2017-06-01 US disclosed
US-9518066-B2 GAK modulators KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2016-12-13 US disclosed
EP-3016958-A1 NOVEL GAK MODULATORS Katholieke Universiteit Leuven (BE) 2016-05-11 EP disclosed
US-20160122364-A1 NOVEL GAK MODULATORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2016-05-05 US disclosed
WO-2016012536-A1 GAK MODULATORS AS ANTIVIRALS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2016-01-28 WO disclosed
WO-2015001076-A1 NOVEL GAK MODULATORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2015-01-08 WO disclosed
EP-1381366-B9 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2009-10-21 EP disclosed
EP-1381366-B1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2009-04-22 EP disclosed
EP-1381366-A4 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
US-6825201-B2 ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS BRISTOL-MYERS SQUIBB COMPANY 2004-11-30 US disclosed
EP-1381366-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-21 EP disclosed
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-05-22 US disclosed
WO-2002085301-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122364-A1 NOVEL GAK MODULATORS GAK, CAMKK2, GRK3 RRM1 2958/4885RRM2 1803/4885RRM2B 1486/4885
US-20170152271-A1 GAK MODULATORS AS ANTIVIRALS GAK, IRF3, EIF2AK2 RRM1 1634/4885RRM2 1109/4885RRM2B 1044/4885
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives IDO1, IDO2, INMT RRM1 4481/4885RRM2 3547/4885RRM2B 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.